drug · protein
lonapegsomatropin LA
Phase 3updated 5mo agoby Ascendis Pharma AS🔗 ChEMBL
Phase 3community read0 votes
Protein drug with a maximum clinical stage of Approval (across all indications), with an approval for pituitary dwarfism and growth delay and 3 investigational indications.
targets
Growth hormone receptor
all catalysts(0)
nothing on the calendar yet
Trials studying lonapegsomatropin LA
News(1)
- Novo walks away from $285M pact to develop monthly GLP-1 obesity drug with AscendisNovo’s attempted rebrand got off to a shaky start this week with the news that the pharma had walked away from a $285 million biobucks pact to develop a monthly weight loss drug after less than two…fiercebiotech · 18d ago
Data sources
last refreshed 2h ago
Found something off?
comments(0)
5-min edit window · permanent after that